Keyphrases
High-risk Human Papillomavirus (HR-HPV)
100%
Phase II Trial
100%
Cetuximab
100%
Palbociclib
100%
Oropharynx Squamous Cell Carcinoma
100%
Objective Response Rate
36%
Objective Response
27%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
18%
Disease Progression
9%
Median Overall Survival
9%
Median Progression-free Survival
9%
Tumor Response
9%
Stable Disease
9%
Duration of Response
9%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
9%
Oropharynx
9%
RECIST 1.1
9%
Cyclin-dependent Kinase 4 (CDK4)
9%
Target Lesion
9%
Platinum Agents
9%
Eligibility Requirements
9%
Medicine and Dentistry
Wart Virus
100%
Oropharynx Squamous Cell Carcinoma
100%
Cetuximab
100%
Palbociclib
100%
Neoplasm
9%
Progression Free Survival
9%
Overall Survival
9%
Disease Exacerbation
9%
Head and Neck Squamous Cell Carcinoma
9%
Oropharynx
9%
Target Lesion
9%
CDK4/6 Inhibitor
9%
Diseases
9%
Pharmacology, Toxicology and Pharmaceutical Science
Human Papillomavirus
100%
Cetuximab
100%
Palbociclib
100%
Oropharynx Squamous Cell Carcinoma
100%
Neoplasm
9%
Progression Free Survival
9%
Overall Survival
9%
Disease Exacerbation
9%
Head and Neck Squamous Cell Carcinoma
9%
Diseases
9%